Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide - An overview

被引:383
作者
Ignarro, LJ
Napoli, C
Loscalzo, J
机构
[1] Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Evans Dept Med, Boston, MA 02118 USA
[2] Univ Calif Los Angeles, Ctr Hlth Sci, Nitr Oxide Res Grp, Los Angeles, CA 90024 USA
[3] Univ Naples Federico II, Dept Med, Naples, Italy
[4] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA
关键词
oxidant stress; cardiovascular pharmacology; endothelium; vascular type; nitric oxide;
D O I
10.1161/hh0102.102330
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nitric oxide (NO) mediates multiple physiological and pathophysiological processes in the cardiovascular system. Pharmacological compounds that release NO have been useful tools for evaluating the pivotal role of NO in cardiovascular physiology and therapeutics. These agents constitute two broad classes of compounds, those that release NO or one of its redox congeners spontaneously and those that require enzymatic metabolism to generate NO. In addition, several commonly used cardiovascular drugs exert their beneficial action, in part, by modulating the NO pathway. Here, we review these classes of agents, summarizing their fundamental chemistry and pharmacology, and provide an overview of their cardiovascular mechanisms of action.
引用
收藏
页码:21 / 28
页数:8
相关论文
共 107 条
[1]   Aspirin [J].
Awtry, EH ;
Loscalzo, J .
CIRCULATION, 2000, 101 (10) :1206-1218
[2]   Nitrosothiol esters of diclofenac: Synthesis and pharmacological characterization as gastrointestinal-sparing prodrugs [J].
Bandarage, UK ;
Chen, LQ ;
Fang, XQ ;
Garvey, DS ;
Glavin, A ;
Janero, DR ;
Letts, LG ;
Mercer, GJ ;
Saha, JK ;
Schroeder, JD ;
Shumway, MJ ;
Tam, SW .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (21) :4005-4016
[3]   Biocompatibility aspects of new stent technology [J].
Bertrand, OF ;
Sipehia, R ;
Mongrain, R ;
Rodés, JR ;
Tardif, JC ;
Bilodeau, L ;
Côté, G ;
Bourassa, MG .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (03) :562-571
[4]   Depletion of intracellular glutathione reduces mutations by nitric oxide-donating drugs [J].
Birnboim, HC ;
Privora, H .
NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 2000, 4 (05) :496-504
[5]   NITRIC-OXIDE MEDIATED VENODILATOR EFFECTS OF NEBIVOLOL [J].
BOWMAN, AJ ;
CHEN, CPLH ;
FORD, GA .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (03) :199-204
[6]  
Brunton L., 1867, LANCET, Vii, P97, DOI [10.1016/S0140-6736(02)51392-1, DOI 10.1016/S0140-6736(02)51392-1]
[7]  
CHUNG SJ, 1990, J PHARMACOL EXP THER, V253, P614
[8]  
Cleophas T.J., 1998, J. Clin. Med, V2, P2
[9]  
COCKCROFT JR, 1995, J PHARMACOL EXP THER, V274, P1067
[10]  
COLLINS R, 1995, LANCET, V345, P669